文献速递中毒与环境急症消化、代谢与肾脏急症

急性草甘膦自服中毒的临床毒理学:草甘膦、其代谢物及聚乙氧基牛脂胺表面活性剂的血浆浓度对毒性的影响

Clinical toxicology of acute glyphosate self-poisoning: impact of plasma concentrations of glyphosate, its metabolite and polyethoxylated tallow amine surfactants on the toxicity.
PubMed 文献 · Clin Toxicol (Phila) · 2024-07-29
一句话结论草甘膦及其代谢物血浆浓度可预测急性肾损伤和死亡,聚乙氧基牛脂胺对急性肾损伤预测更强但仅少数患者可检出。

该研究纳入2010至2013年间151例急性草甘膦中毒患者,于2020年用液相色谱-串联质谱测定草甘膦、代谢物氨甲基膦酸及聚乙氧基牛脂胺的血浆浓度。草甘膦和氨甲基膦酸预测急性肾损伤(≥2级)的曲线下面积分别为0.83(95%CI 0.69-0.97)和0.76(95%CI 0.59-0.94),预测死亡的曲线下面积均>0.9。聚乙氧基牛脂胺仅在约五分之一有症状患者中检出,包括四例死亡中的一例,其不饱和牛脂部分对急性肾损伤预测良好(曲线下面积≥0.7)。随牛脂部分中重复乙氧基单元数减少,急性肾损伤的比值比增加。病例病死率为2.7%,49%发生急性(尽管轻微)肾损伤。

要点

  • 草甘膦血浆浓度预测急性肾损伤(≥2级)的AUC为0.83(95%CI 0.69-0.97),氨甲基膦酸为0.76(95%CI 0.59-0.94)。
  • 草甘膦和氨甲基膦酸血浆浓度预测死亡的AUC均>0.9,为极佳预测指标。
  • 聚乙氧基牛脂胺仅在约五分之一有症状患者中检出,包括四例死亡中的一例,其不饱和牛脂部分预测急性肾损伤的AUC≥0.7。
  • 随牛脂部分中重复乙氧基单元数减少,急性肾损伤的比值比增加。
  • 该队列病死率2.7%,49%发生急性(尽管轻微)肾损伤,与既往数据一致。

适用人群与场景

  • 2010至2013年间纳入的151例急性草甘膦中毒患者。

诊断标准与关键阈值

  • 急性肾损伤判定为≥2级。

研究设计与关键结果

  • 研究类型为队列研究,纳入151例急性草甘膦中毒患者,于2020年用液相色谱-串联质谱测定草甘膦、氨甲基膦酸和聚乙氧基牛脂胺血浆浓度。
  • 草甘膦预测急性肾损伤(≥2级)的AUC为0.83(95%CI 0.69-0.97),氨甲基膦酸为0.76(95%CI 0.59-0.94)。
  • 聚乙氧基牛脂胺在约五分之一有症状患者中检出,包括四例死亡中的一例;其不饱和牛脂部分预测急性肾损伤的AUC≥0.7。
  • 随牛脂部分中重复乙氧基单元数减少,急性肾损伤的比值比增加。
  • 草甘膦和氨甲基膦酸预测死亡的AUC均>0.9。
  • 病死率为2.7%,49%发生急性(尽管轻微)肾损伤。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,使用基于模型的指标的人群方法可能更好地探索暴露与中毒严重程度的关系。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Common major co-formulants in glyphosate-based herbicides, polyethoxylated tallow amine surfactants, are suspected of being more toxic than glyphosate, contributing to the toxicity in humans. However, limited information exists on using polyethoxylated tallow amine concentrations to predict clinical outcomes. We investigated if plasma concentrations of glyphosate, its metabolite and polyethoxylated tallow amines can predict acute kidney injury and case fatality in glyphosate poisoning.

METHODS: We enrolled 151 patients with acute glyphosate poisoning between 2010 and 2013. Plasma concentrations of glyphosate, its metabolite, aminomethylphosphonic acid, and polyethoxylated tallow amines were determined in 2020 using liquid chromatography-tandem mass spectrometry. Associations between exposure and poisoning severity were assessed.

RESULTS: Plasma concentrations of glyphosate and aminomethylphosphonic acid demonstrated good and moderate performances in predicting acute kidney injury (≥2), with an area under the receiver operating characteristic curve of 0.83 (95% CI 0.69-0.97) and 0.76 (95% CI 0.59-0.94), respectively. Polyethoxylated tallow amines were detected in one-fifth of symptomatic patients, including one of four fatalities and those with unsaturated tallow moieties being good indicators of acute kidney injury (area under the receiver operating characteristic curve ≥0.7). As the number of repeating ethoxylate units in tallow moieties decreased, the odds of acute kidney injury increased. Glyphosate and aminomethylphosphonic acid concentrations were excellent predictors of case fatality (area under the receiver operating characteristic curve >0.9).

DISCUSSION: The 2.7% case fatality rate with 49% acute, albeit mild, acute kidney injury following glyphosate poisoning is consistent with previously published data. A population approach using model-based metrics might better explore the relationship of exposure to severity of poisoning.

CONCLUSIONS: Plasma concentrations of glyphosate and its metabolite predicted the severity of clinical toxicity in glyphosate poisoning. The co-formulated polyethoxylated tallow amine surfactants were even more strongly predictive of acute kidney injury but were only detected in a minority of patients.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Qiang S, Mohamed F, Raubenheimer J, et al. Clinical toxicology of acute glyphosate self-poisoning: impact of plasma concentrations of glyphosate, its metabolite and polyethoxylated tallow amine surfactants on the toxicity. Clin Toxicol (Phila). 2024. PMID: 39073455. doi:10.1080/15563650.2024.2375584

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。